Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Dalargin
Overview
Dalargin is a synthetic hexapeptide analog of leucine-enkephalin with enhanced metabolic stability due to D-amino acid substitutions. It acts as a selective delta opioid receptor agonist with peripheral and central effects, including modulation of stress responses, anti-inflammatory activity, and cytoprotection in gastrointestinal and vascular tissues.
Mechanism of Action
Unlike classical opioids, dalargin exhibits reduced central analgesic potency but pronounced tissue-protective properties.
Research Summary & Key Findings
Dalargin has been used clinically in Russia and some Eastern European countries for treatment of gastric ulcers, pancreatitis, and stress-related mucosal injury since the 1980s. Peer-reviewed evidence in Western literature is limited, with most data derived from Soviet-era clinical studies and pharmacological characterization in animal models.
Clinical Status
Dalargin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Dalargin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Dalargin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Dalargin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Recovery
BPC-157
Research PhaseA synthetic gastric pentadecapeptide derived from a protein found in human gastric juice. BPC-157 promotes angiogenesis ...
View detailsTB-500 (Thymosin Beta-4)
In Clinical TrialsThymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue re...
View detailsGHK-Cu
Research PhaseA naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. G...
View detailsDSIP (Delta Sleep-Inducing Peptide)
Research PhaseA naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood o...
View detailsNo lawful pathway today
Dalargin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.